The Efficacy of Nigella Sativa Oil Mouth Rinse in the Management of Recurrent Minor Aphthous Ulcer
Aphthous Ulcer
About this trial
This is an interventional other trial for Aphthous Ulcer focused on measuring recurrent, aphthous ulcer, minor, nigella sativa, mouth rinse
Eligibility Criteria
Inclusion Criteria: All patients should be free from any systemic disease or Behcet syndrome (Atai et al., 2007). Patients male or female are eligible (Epstein et al., 2018). Oral pain score of 4 or higher on a scale of 0-10 with 0 representing no pain in the presence of oral ulceration (Epstein et al., 2018). Patient has only minor aphthous ulcer and its diameter should be less than 1 cm (Atai et al., 2007). It should had not been passed more than 4 days from beginning of their ulcer (Atai et al., 2007). Exclusion Criteria: Patients with poor oral hygiene or not willing to perform oral hygiene measures. Smoking and alcohol use. Pregnant and lactating females. Patients with history of any topical or systemic medication or steroid therapy 1 month prior to the investigation (Chaudhuri et al., 2018).
Sites / Locations
- Nada Mohamed Sherif Aly abdelhamid
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Group 1 (TEST GROUP) Nigella Sativa oil mouth rinse
Group 2 (CONTROL GROUP)
Ten patients will receive Nigella Sativa oil mouth rinse. Patients will be asked to use the NS oil mouth rinse (10 ml each 6 hrs.) four times daily . Subjects will be provided with 72 hours supply of the study product. Patients will be instructed to use it for 72 hours with a minimum frequency of four times per day, swished for one minute at each use, in which the first dose was used upon awakening and the last dose just before evening sleep. Patients will be instructed not to use over the counter (OTC) or pharmacy formulated oral rinses or gels during the active treatment phase.
Ten patients will receive the placebo isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl). Patients will be asked to use it as mouth rinse (10 ml each 6 hrs.) four times daily . Subjects will be provided with 72 hours supply of the study product. Patients will be instructed to use it for 72 hours with a minimum frequency of four times per day, swished for one minute at each use, in which the first dose was used upon awakening and the last dose just before evening sleep. Patients will be instructed not to use over the counter (OTC) or pharmacy formulated oral rinses or gels during the active treatment phase.